BRTX Stock Price Increased 30% Today: Why It Happened – Pulse 2.0

The stock price of BioRestorative Therapies Inc (OTCMKTS: BRTX) a company that develops therapeutic products using cell and tissue protocols primarily involving adult stem cells increased by 30% today as it went from $0.010 in the previous close to a day high of $0.013 today. One of the biggest triggers appears to be tweets from an account that is associated with the new CEO of the company Lance Alstodt: About three weeks ago, it was announced that BioRestorative Therapies was emerging from Chapter 11 reorganization

Read more
Year in Review: Hematologic Malignancies – MedPage Today

The year in hematologic malignancy management was punctuated by the deadly COVID-19 pandemic, a flurry of FDA approvals ushering in new therapies, and continued steady advances in cellular products and other treatments for leukemia, lymphoma, multiple myeloma, and other cancers of the blood. COVID-19 Especially Risky in Blood Cancer No story in 2020 dominated the news more than the COVID-19 pandemic, and early data emerged suggesting the virus was particularly deadly in patients with hematological cancers

Read more
BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute…

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical Products Administration (NMPA) has approved BLINCYTO (blinatumomab) for injection for the treatment of adult patients with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL). The biologics license application (BLA) had been submitted by Amgen and received priority review by the Center for Drug Evaluation (CDE) of the NMPA.

Read more